Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential
Source: Streetwise Reports  (3/9/26)
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%. More >

Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory
Source: Dr. Douglas Loe  (3/6/26)
Leede Financial maintains its current rating on CareRx and raised its target price, following FQ425 results showing continued sequential improvement in EBITDA, margins, and operating cash flow. More >

Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M
Source: Nicholas Cortellucci  (3/5/26)
Atrium Research initiated coverage on Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30. More >

Biotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing
Source: Streetwise Reports  (3/5/26)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) successfully secured financing transactions totaling CA$7.1 million, significantly bolstering the company's financial stability. Find out how one analyst rates the stock. More >

Biotech Expands Financing to CA$2M as AI-Driven Cancer Drug Programs Advance
Source: Streetwise Reports  (2/24/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) increased its previously announced financing to approximately US$2.0 million through a convertible debenture and private placement. The company stated the proceeds will support working capital needs and ongoing corporate and strategic initiatives. More >

New Data, Analyst Calls, and Pipeline Milestones Put Spotlight on Next Wave of Weight-Loss Drug Developers
Source: Streetwise Reports  (2/18/26)
Eli Lilly (LLY:NYSE), Amgen (AMGN:NASDAQ), and Structure Therapeutics (GPCR:NASDAQ) were cited in recent reports and corporate updates tied to the expanding GLP-1 and obesity treatment market. Analyst commentary, clinical developments, and pipeline milestones highlighted ongoing activity across the sector. More >

Biotech Company Advances Breakthrough Hyperinsulinism Treatment
Source: Streetwise Reports  (2/13/26)
Rezolute Inc. (RZLT:NASDAQ), a late-stage company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), reports its financial results and provides a business update for the three months ending December 31, 2025. Read why one analyst considers the stock a Buy. More >

Technically Oversold with Support, Solid Patents, & A Heavyweight Board: Is This Stock Set to Soar?
Source: Stewart Thomson  (2/10/26)
Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys board and scientific advisory team of seasoned pros includes Dr. Patrick Vink (M.D., M.B.A.), Chairman of the Board, and Dr. Dan Muruve (M.D.), Chief Scientific Officer and internationally recognized nephrologist. The technical action on the charts suggests a significant surge in the stock price could be imminent. More >

CleanTech Company Advances FDA-Cleared Solution Toward Big Gains
Source: Streetwise Reports  (2/10/26)
Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives. More >

Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies
Source: Streetwise Reports  (2/9/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates. More >

FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results
Source: Streetwise Reports  (2/6/26)
TuHURA Biosciences Inc. (HURA:NASDAQ) said the FDA granted Orphan Drug Designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma. The designation was based on data from the companys previously completed Phase 1 clinical study. More >

Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study
Source: Streetwise Reports  (2/2/26)
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year. More >

Biopharma Reaches 50% Enrollment in New ALS Drug Program
Source: Jason Kolbert  (2/2/26)
MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm. More >

Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market
Source: Streetwise Reports  (1/30/26)
Biopharmaceutical firm MediciNova Inc. (MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year. More >

Report of FDA Drug Approval Delay is 'Likely Noise': Analyst
Source: Douglas Tsao  (1/27/26)
Disc Medicine Inc.'s (IRON:NASDAQ) chances of bitopertin getting approved remain unaltered by the claims in a recent article, noted an H.C. Wainwright & Co. report. Read on to learn the reasons behind this opinion of the investment bank. More >

Analysts Highlight Notable H1/26 Catalysts in Biotech
Source: RBC Capital Markets  (1/12/26)
Despite the overall run-up in biotech names last year, the sector still offers "several attractive H1/26 catalyst set-ups, noted an RBC Capital Markets report. Find out which upcoming events the analysts like the most and the least. More >

AI Collaboration Expands to Accelerate Cancer Drug Discovery
Source: Streetwise Reports  (1/12/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) has broadened its partnership with Variational AI to refine next-generation ATR inhibitors using generative AI. The agreement aims to streamline lead optimization for the company's kt-5000 series of small-molecule cancer drug candidates. More >

Expanded AI Collaboration Advances Optimization of Cancer Drug Candidates
Source: Streetwise Reports  (1/9/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) has expanded its partnership with Variational AI to advance optimization of its kt-5000 ATR inhibitor series. Learn how the agreement deepens the company's use of generative AI to refine small-molecule drug candidates and accelerate preclinical selection. More >

Clean-Tech Co. Looks Forward to Massive Market Breakthroughs in 2026
Source: Streetwise Reports  (12/31/25)
BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert notes the company is looking forward to its part in "what may be one of the largest infrastructure and technology investment cycles in history." More >

Clean-Tech Firm Anticipates Major Market Advancements in 2026
Source: Streetwise Reports  (12/30/25)
Dennis P. Calvert, President and CEO of BioLargo Inc. (BLGO:OTCQX), mentions that the company is eager to participate in "what may be one of the largest infrastructure and technology investment cycles in history." More >

Mineral Investor Chen Lin Argues Silver Moving From Bullion to Physical Asset, Reveals Picks
Source: Streetwise Reports  (12/16/25)
Seasoned minerals investor Chen Lin argues silver's 50-year breakout is not a routine cycle but a transition from bullion to a tightening "critical minerals" market. Read on to see what some of his top picks are, including one biotech company he thinks could be the next Eli Lilly. More >

Market Experts Uncover Excellent Buys During December 'Silly Season' Tax Selloff
Source: Streetwise Reports  (12/15/25)
Every December, tax-loss selling tends to exert downward pressure on certain stocks as investors aim to offset capital gains. Streetwise Reports asked some of its frequent contributors to add their own thoughts on the other "holiday season" and give their own picks for good bargains. More >

Data on 2 Drugs, Identified Via AI, Shared at Conference
Source: Dr. Douglas Loe  (12/4/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report. More >

AI Breakthroughs Drive New Momentum in Oncology Research
Source: Streetwise Reports  (12/3/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) reported financial and operational results for Q3, detailing continued progress across its AI-enabled DNA Damage Response programs. The company highlighted new scientific data, expanded collaborations, and increased visibility at major oncology conferences. More >

Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive
Source: Streetwise Reports  (12/1/25)
Alto Neuroscience Inc. (ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma. More >